Πέμπτη 8 Μαρτίου 2018

Treating ERBB2/HER-2 –Negative Breast Cancer With Nab-paclitaxel

This randomized clinical trial determines whether nab-paclitaxel improves the outcomes of early and locally advanced ERBB2/HER2-negative breast cancer compared with paclitaxel when delivered in a neoadjuvant setting.

from Cancer via ola Kala on Inoreader http://ift.tt/2D5qgp1
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου